Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
multiple myeloma | — | D009101 | C90.0 |
Expiration | Code | ||
---|---|---|---|
talquetamab, Talvey, Janssen Biotech, Inc. | |||
2030-08-09 | Orphan excl. |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple myeloma | D009101 | — | C90.0 | 5 | 3 | 2 | — | 1 | 10 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hematologic neoplasms | D019337 | — | — | 1 | 1 | — | — | — | 2 |
Drug common name | Talquetamab |
INN | talquetamab |
Description | Talquetamab, sold under the brand name Talvey, is a humanized monoclonal antibody used for the treatment of multiple myeloma. It is a bispecific GPRC5D-directed CD3 T-cell engager. Talquetamab is a bispecific antibody against two targets: human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen with potential antineoplastic activity. Talquetamab binds both targets, drawing the T cells close to the tumor cells, causing a cytotoxic T-lymphocyte response. It is being developed by Janssen Pharmaceuticals.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | 2226212-40-2 |
RxCUI | — |
ChEMBL ID | CHEMBL4594503 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB16678 |
UNII ID | 4W3KFI3TN3 (ChemIDplus, GSRS) |